Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of deucravacitinib in adolescents with moderate to severe plaque psoriasis
MOH_2026-08-09_016974Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deucravacitinib in plaque psoriasis (4 arms), sponsored by Bristol Myers Squibb. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on MOH_2026-08-09_016974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-09_016974.